Comparison of different thawing protocols in human cryopreserved venous grafts.

Comparison of different thawing protocols in human cryopreserved venous grafts.

The purpose of our study is to assess the impact of different disbursement protocols in morphological changes that arise in the grafting of cryopreserved human saphenous veins. This study was conducted on twelve saphenous vein grafts harvested on brain death donors. Storage in the liquid nitrogen phase for 3 or 5 years is followed. Two Disbursement Protocols are tested: 1. Giving birth in the refrigerator at + 4 ° C for 2 hours. 2. Fast Disbursement – In Tub Water at + 37 ° C. Graft is processed to scan an electron microscope. Comparison of continuous parameters in the study between experimental groups is carried out using T-Test (age, cold ischemic time, Cryoprotectant exposure, time of storage, total disbursement time, melting average, melted HSVG morphological assessment) and median test (HSVG length).

Categorical parameters (gender, blood group) are officially tested using the Chi-Square test. All samples are evaluated in accordance with morphological changes and scores in terms of mutually morphological endothelium, endothelum that supports structural inhomogenity, endothelial cell separation, separation, loss of endothelium and damage to the subendotial layer. There was no statistically significant difference between the sample set at a significance level of 0.05. There is no relationship with donor ages, gender and storage time. Graft Vena Saphenous Cryopreserved in our experimental work does not show the difference in terms of structural damage to endothelial surfaces and basal membranes depending on the liquefaction protocol used.

Cryopreserved human umbilical straps versus dermal acellular matrix patches for improving the Fetal Spina Bifida Fetal in the Pregnant Mouse Model.

Apart from a significant increase in the spinal cord function after the improvement of the Utero Spina Bifida (SB) compared to traditional postnatal improvements, more than half of the children who undergo this procedure did not benefit fully. The lack of benefits has been associated with the method of closing defects, with the next spinal cord tethering on the repair site. Therefore, regenerative fillings or materials with anti-inflammatory and anti-scar properties can relieve comorbidity with improved results.

Therefore the main goal of the author to compare the umbilical cable of the human cryopreserved (HUC) versus acellular dermal matrix (ADM) for regenerative repairs in the Uterero SB lesion in the animal model. In Vivo’s studies were carried out in the defect of SB which was induced by Retino acid in the Fetus of the Tikus Sprague-Dawley. Huc or ADM patches are sewn on the disability of SB at a 20 day gestation. The SB defective network that was repaired was harvested after 48-52 hours.

The network section is directed immunofluorescent to the existence of neutrophils, macrophages, keratinocytes, meningeal cells, and astrocytes and for related apoptosis. Experiments of cokultur meningeal cells or keratinocytes with ADM patch and HUC are carried out. All experiments are considered quantitatively in a blind manner. Nekrofil counts and lower apoptosis cells in the HUC-based improvement group (N = 8) rather than in the admin repair group (n = 7).

In the Huc Patch Repair Group, Keratinocytes are present on the outer surface of the patch, the meningeal cell is present on the surface of the inner surface adjacent to the neurlassode, and the astrocyte is not recorded. In the ADM patch repair group, all 3 types of cells are on both patch surfaces. In vitro studies show that human meningeal cells grow specially on the Mesenchymal Patch Huc side, while keratinocytes show tropism for the epithelial side, indicating the polarity based cells based. In contrast, ADM patch studies do not show the polarity and decrease in cellular infiltration.

A strong protocol for the free feeder adaptation of Cryopreserved pluripotent stem cells.

Human pluripotent stem cells (HPSCs) are managed conventionally in the embryon fibroblast feeder (MEF) mouse layer. However, downstream applications, such as directed differentiation protocols, are mainly optimized for Feeder-Free culture. Therefore, HPSCs must often be adapted to the free condition of the feeder. Here we propose a new free feeder adaptation protocol using Stemflex media, which can be directly applied to the liqueficible HPSC line. The free adaptation protocol of the feeder directly using Stemflex’s culture media in the Geltrex layer causes a strong HPSC culture in about 2 weeks.

Comparison of different thawing protocols in human cryopreserved venous grafts.

This approach was tested with three human embryonic stem cell lines (HESC). All lines are confirmed to be pluripotent, expressing POU5F1, SOX2, and Nanog. No chromosome imbalance induced by the adaptation of feeder-free protocol is easily implemented in the laboratory that conducts a free culture of feeders, allowing more comfortable adaptation and stronger expansion of HPSC cryopreserved, even in cases when the sample quality is low or unknown.

The effects of human amniotic membranes cryopreserved on healing fracture: studies of animals.

The purpose of this study was to investigate the effects of human amniotic membranes (HAM) in healing fractures on animal models. Tibial diapial fractures can be created in twenty eight wistar-albino rats and treated with Kirschner intramedulller (K-Wire) wire and human rights (HAM (+)) or K-wire group (HAM (-)). Fracture healing is evaluated with histological analysis, radiological x-ray display and callus diameter measurement in 3 and 6 weeks postoperative postoperatively better in human rights group (+) and the difference is statistically significant in the 3rd and 6th week of post operation (p <0.05). The highest histological score and all the formation of woven bones (HUO Stage 8-9) was obtained in 6 weeks after surgery in the human rights group (+). Histological examination also revealed the dominant fibrous network and the formation of partial cartilage (HUO stage 2) in the 3rd week after surgery in the human rights group (-).

T-Pro MycoClean spray

JT90-R002 500ml/BT
EUR 172.8

CD4+ T cells, Negatively Selected (Human)

79752 10 million cells
EUR 395
Description: Cryopreserved vial (10 x 10^6 cells) of CD4+ T cells that were negatively selected from freshly isolated primary human peripheral blood mononuclear cells (PBMCs). The PBMCs came from a healthy donor, and were isolated from whole blood or leukapheresis samples using a Ficoll gradient. Magnetic antibodies to monocytes, granulocytes, CD8+ T cells, gamma/delta T cells and other immune subsets present in PBMCs were then used to purify untouched CD4+ T cells via immunomagnetic separation. Before and after CD4+ T cell isolation, the cells were stained to evaluate purity and viability by flow cytometry. Cells were cryopreserved in CryoStor CS10 cryopreservation medium (Stemcell, #07930) at a controlled rate._x000D_Source
Normal human PBMC from Leukapheresis Sample

CD8+ T cells, Negatively Selected (Human)

79753 10 million cells
EUR 495
Description: Cryopreserved vial (10 x 10^6 cells) of CD8+ T cells that were negatively selected from freshly isolated primary human peripheral blood mononuclear cells (PBMCs). The PBMCs came from a healthy donor, and were isolated from whole blood or leukapheresis samples using a Ficoll gradient. Magnetic antibodies to monocytes, granulocytes, CD4+ T cells, gamma/delta T cells and other immune subsets present in PBMCs were then used to purify untouched CD8+ T cells via immunomagnetic separation. Before and after CD8+ T cell isolation, the cells were stained to evaluate purity and viability by flow cytometry. Cells were cryopreserved in CryoStor CS10 cryopreservation medium (Stemcell, #07930) at a controlled rate._x000D_Source
Normal human PBMC from Leukapheresis Sample

T-Pro EZ Gel Solution 8%

JB02-B008M 500ml/BT
EUR 266.4

T-Pro EZ Gel Solution 8%

JB02-B008S 100ml/BT
EUR 162

T-Pro EZ Gel Solution 10%

JB02-B010M 500ml/BT
EUR 266.4

T-Pro EZ Gel Solution 10%

JB02-B010S 100ml/BT
EUR 162

T-Pro EZ Gel Solution 12%

JB02-B012M 500ml/BT
EUR 266.4

T-Pro EZ Gel Solution 12%

JB02-B012S 100ml/BT
EUR 162

T-Pro EZ Gel Solution 15%

JB02-B015M 500ml/BT
EUR 266.4

T-Pro EZ Gel Solution 15%

JB02-B015S 100ml/BT
EUR 162

T-Pro Separating or Resolving Buffer

JB03-C001 500ml/BT
EUR 182.4

T-Pro BCA Protein Assay kit

JB04-D001 500assay/KIT
EUR 244.8

T-Pro Transfer Blotting buffer (10X)

JB08-H001 500ml/BT
EUR 162

T-Pro Western Blot Stripping Reagent

JB11-K002 500ml/BT
EUR 213.6

T-Pro Aqua EZ Clean (M)

JT90-R001M 500ml/BT
EUR 398.4

T-Pro Aqua EZ Clean (S)

JT90-R001S 100ml/BT
EUR 181.2

T-Pro EZ stain Gel solution

JT90-R005M 500ml/BT
EUR 224.4

T-Pro EZ stain Gel solution

JT90-R005S 100ml/BT
EUR 151.2

T-Pro P-Fect Transfection Reagent

JT97-N005M 1.0ml/vial
EUR 266.4

T-Pro Plasmid Mini Kit (100)

RB94-YPD100 100preps/Kit
EUR 193.2

T-Pro Plasmid Mini Kit (250)

RB94-YPD250 250preps/Kit
EUR 266.4

T-Pro Plasmid Midi Kit (20)

RB94-YPI020 20preps/Kit
EUR 255.6

T-Pro Plasmid Maxi Kit (10)

RB94-YPM010 10preps/Kit
EUR 266.4

T-Pro BCA Protein Assay Reagent A

JB04-D001A 500ml/BT
EUR 204

T-Pro BCA Protein Assay Reagent B

JB04-D001B 12ml/BT
EUR 140.4

T-Pro Bradford Protein Assay kit(1X)

JB04-D002 500ml/BT
EUR 193.2

T-Pro Fast Blocking Buffer (in PBS)

JK92-W001 500ml/BT
EUR 224.4

T-Pro Fast Blocking Buffer (in TBS)

JK92-W002 500ml/BT
EUR 224.4

T-Pro Genomic DNA Midi Kit (20)

RB94-NGM020 20preps/kit
EUR 266.4

T-Pro Genomic DNA Mini Kit (100)

RB94-NGS100 100preps/kit
EUR 255.6

T-Pro Laemmli (SDS sample) Reagent (reducing 4X)

JB06-F002 10ml/BT
EUR 151.2

T-Pro Tris-Glycine-SDS running buffer (10X)

JB07-G001 500ml/BT
EUR 162

T-Pro Tris-Glycine-Native running buffer (10X)

JB07-G002 500ml/BT
EUR 162

T-Pro Semi Dry Transfer Blotting buffer (10X)

JB08-H002 500ml/BT
EUR 172.8

T-Pro Protein Free Blocking Buffer (in PBS)

JK92-W003 500ml/BT
EUR 224.4

T-Pro Protein Free Blocking Buffer (in TBS)

JK92-W004 500ml/BT
EUR 224.4

T-Pro Nonliposomal Transfection Reagent I (NTR I)

JT97-N001M 1.0ml/vial
EUR 224.4

T-Pro Nonliposomal Transfection Reagent II (NTR II)

JT97-N002M 1.0ml/vial
EUR 244.8

T-Pro Nonliposomal Transfection Reagent III (NTR III)

JT97-N006M 1.0ml/vial
EUR 266.4

T-Pro Endotoxin Removal Plasmid Midi kit (25)

RB94-EPI020 20preps/Kit
EUR 297.6

T-Pro Endotoxin Removal Plasmid Maxi kit (10)

RB94-EPM010 10preps/Kit
EUR 318

T-Pro Plant Genomic DNA Midi Kit (20)

RB94-PGM020 20preps/kit
EUR 266.4

T-Pro Plant Genomic DNA Mini Kit (100)

RB94-PGS100 100preps/kit
EUR 266.4

T-Pro Laemmli (SDS sample) Reagent (non-reducing 4X)

JB06-F003 10ml/BT
EUR 151.2

T-Pro LumiFast Plus Chemiluminescence Detection Kit (ECL Kit)

JT96-K002M 250ml*2/Kit
EUR 244.8

T-Pro LumiFast Plus Chemiluminescence Detection Kit (ECL Kit)

JT96-K002S 100ml*2/Kit
EUR 182.4

T-Pro LumiLong Plus Chemiluminescence Detection Kit (ECL Kit)

JT96-K004M 250ml*2/Kit
EUR 286.8

T-Pro LumiLong Plus Chemiluminescence Detection Kit (ECL Kit)

JT96-K004S 100ml*2/Kit
EUR 204

T-Pro Gel/PCR DNA Purification Maxi Kit (10)

RB94-NEL010 10preps/Kit
EUR 193.2

T-Pro Gel/PCR DNA Purification Mini Kit (100)

RB94-NES100 100preps/Kit
EUR 193.2

T-Pro Gel/PCR DNA Purification Mini Kit (250)

RB94-NES250 250preps/Kit
EUR 266.4

T-Pro Washing buffer in PBS and Tween-20 (10X)

JB09-I003 500ml/BT
EUR 172.8

T-Pro Washing buffer in TBS and Tween-20 (10X)

JB09-I004 500ml/BT
EUR 172.8

T-Pro Phosphate-Buffered Saline (PBS, 10X) for western blot washing

JB09-I001 500ml/BT
EUR 162

T-Pro Tris-Buffered Saline (TBS, 10X) for western blot washing

JB09-I002 500ml/BT
EUR 162

Untransduced T Cells

78170-1 1 vial
EUR 1250
Description: The untransduced T cells are produced by mock lentiviral transduction of human primary CD4+CD8+ T cells. These cells are subjected to comparable manipulations as CAR-T cells: activation, spinoculation (without lentivirus), and expansion. These T cells are meant to be negative controls in experiments using lentivirus-transduced primary CAR-T cells.

Untransduced T Cells

78170-2 5 vials
EUR 3325
Description: The untransduced T cells are produced by mock lentiviral transduction of human primary CD4+CD8+ T cells. These cells are subjected to comparable manipulations as CAR-T cells: activation, spinoculation (without lentivirus), and expansion. These T cells are meant to be negative controls in experiments using lentivirus-transduced primary CAR-T cells.

Human Normal Peripheral Blood CD4+/CD25+ Regulatory T Cells (T reg), Fresh

PBCD4-25-F2M - Ask for price

Human Normal Peripheral Blood CD4+/CD25+ Regulatory T Cells (T reg), Cryopreserved

PBCD4-25-C2M - Ask for price

Human Cord Blood CD34+ Cells Derived Endothelial Cells

HEC23 500,000+ Cells
EUR 1296

Anti-CD19 CAR-T Cells

78171-1 1 vial
EUR 1595
Description: The anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector, BPS Bioscience, #78601). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

Anti-CD19 CAR-T Cells

78171-2 5 vials
EUR 4250
Description: The anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains.These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

Anti-BCMA CAR-T Cells

78660-1 1 vial
EUR 1595
Description: The anti-BCMA CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-BCMA CAR Lentivirus (BPS Bioscience #78655). These ready-to-use CAR-T cells express an anti-BCMA CAR consisting of the ScFv of BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

Anti-BCMA CAR-T Cells

78660-2 5 vials
EUR 4250
Description: The anti-BCMA CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-BCMA CAR Lentivirus (BPS Bioscience #78655). These ready-to-use CAR-T cells express an anti-BCMA CAR consisting of the ScFv of BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

anti-CD4 T helper cells

502-A-01mg 0,1 mg
EUR 321
Description: anti-CD4 T helper cells

anti-CD4 T helper cells

502-A-1000ug 1000 ug
EUR 1539
Description: anti-CD4 T helper cells

anti-CD4 T helper cells

502-A-100ugvial 100 ug/vial
EUR 150
Description: anti-CD4 T helper cells

Human T- cell- interacting, activating receptor on myeloid cells

ELI-41653h 96 Tests
EUR 988.8

Immortalized Human Mucosal Associated Invariant T Cells (EM-C5)

T0706 1x106 cells / 1.0 ml Ask for price

Immortalized Human Mucosal Associated Invariant T Cells (JK-A8)

T0708 1x106 cells / 1.0 ml Ask for price

Immortalized Human Mucosal Associated Invariant T Cells (MG-A4)

T0709 1x106 cells / 1.0 ml Ask for price

Immortalized Human Mucosal Associated Invariant T Cells (EM-B11)

T0705 1x106 cells / 1.0 ml Ask for price

Immortalized Human Mucosal Associated Invariant T Cells (IK-B12)

T0707 1x106 cells / 1.0 ml Ask for price

Human Schwann Cells

HMP303 500,000 Cells - Frozen
EUR 1420.8

anti-CD8 T cytotoxic/supressor cells

505-A-01mg 0,1 mg
EUR 321
Description: anti-CD8 T cytotoxic/supressor cells

anti-CD8 T cytotoxic/supressor cells

505-A-1000ug 1000 ug
EUR 1539
Description: anti-CD8 T cytotoxic/supressor cells

anti-CD8 T cytotoxic/supressor cells

505-A-100ugvial 100 ug/vial
EUR 150
Description: anti-CD8 T cytotoxic/supressor cells

Human Nuclear factor of activated T- cells 5, NFAT5 ELISA KIT

ELI-39512h 96 Tests
EUR 988.8

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC942884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF594 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC942884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF594 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC802884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF680 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC802884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF680 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC702884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF770 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC702884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF770 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC882884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF488A conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC882884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF488A conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC812884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF680R conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC812884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF680R conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC402884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF640R conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC402884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF640R conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC052884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF405M conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC052884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF405M conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC042884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF405S conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC042884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF405S conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCAP2884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCAP2884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCA2884-250 250uL
EUR 472.8
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), APC conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCP2884-250 250uL
EUR 472.8
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), PerCP conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCR2884-250 250uL
EUR 472.8
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), RPE conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCH2884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCH2884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCB2884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Biotin conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNCB2884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Biotin conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNUB2884-100 100uL
EUR 316.8
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Concentration: 0.2mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNUB2884-50 50uL
EUR 486
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), 1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNUB2884-500 500uL
EUR 615.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Concentration: 0.2mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC472884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF647 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC472884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF647 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC552884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF555 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC552884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF555 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC612884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF660R conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC612884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF660R conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC432884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF543 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC432884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF543 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC682884-100 100uL
EUR 279.6
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF568 conjugate, Concentration: 0.1mg/mL

CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody

BNC682884-500 500uL
EUR 654
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF568 conjugate, Concentration: 0.1mg/mL

Human Melanoma antigen recognized by T- cells 1, MLANA ELISA KIT

ELI-03589h 96 Tests
EUR 988.8

Human T- cell surface glycoprotein CD3 zeta, CD247 ELISA Kit

ELI-33983h 96 Tests
EUR 988.8

Albumin Standard (2.0 mg/ml)

JB04-D001C 5*1ml/kit
EUR 162

Human Bone Marrow CD34+ Stem Cells, Fresh

BMCD34-F0.5M - Ask for price

Human Bone Marrow CD34+ Stem Cells, Fresh

BMCD34-F5M - Ask for price

Human Mesenchymal Stem Cells

SC00A1 500000
EUR 1086

CORNING®HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS, HUVEC-2 CELLS (>5X105 CELLS), 1 CRYOVIAL/PACK

354151 1/pk
EUR 465.6
Description: Permeable Support - DL; Coated Transwells - DL

anti-CD38 Hematopoietic precursors, thymocytes, activated T-cells, plasma cells

514-A-100ugvial 100 ug/vial
EUR 150
Description: anti-CD38 Hematopoietic precursors, thymocytes, activated T-cells, plasma cells

Immortalized Human Colon Cells

T0570 1x106 cells / 1.0 ml Ask for price

Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) ELISA kit

E01N0544-192T 192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) ELISA kit

E01N0544-48 1 plate of 48 wells
EUR 624
Description: A competitive ELISA for quantitative measurement of Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) ELISA kit

E01N0544-96 1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Immortalized Human Lingual Cells

T0042 1x106 cells / 1.0 ml Ask for price

Immortalized Human Dendritic Cells

T0525 1x106 cells / 1.0 ml Ask for price

Immortalized Human Mesangial Cells

T0612 1x106 cells / 1.0 ml Ask for price

Jurkat Nuclear Extract (Acute T cell leukemia cells)

NJKT-100 100 ug
EUR 196.8

Jurkat Nuclear Extract (Acute T cell leukemia cells)

NJKT-50 50 ug
EUR 153.6

Human ES2 / GFP Stable Cells

SC066-G 2 x 106 cell/ml x 1ml
EUR 1800
Description: GFP expression stable cell line in Human ES2 cells with Puromycin resistance

Human ES2 / RFP Stable Cells

SC066-R 2 x 106 cell/ml x 1ml
EUR 1800
Description: RFP expression stable cell line in Human ES2 cells with Puromycin resistance

Normal Human Peripheral Blood Mononuclear Cells, Frozen -100 million cells

79059-2 100 million cells
EUR 580
Description: Cryopreserved vial (30 x 10^6 cells) of freshly isolated primary human peripheral blood mononuclear cells (PBMCs) from a healthy donor, isolated from leukapheresis / apheresis samples using Ficoll gradient. After isolation, the PBMCs were stained to identify sub populations and evaluated for viability by flow cytometry. Cells were cryopreserved in serum-free Cryostor CS10 at a controlled rate.

Immortalized Human Testicular Cells

T0603 1x106 cells / 1.0 ml Ask for price

Immortalized Human Urothelial Cells

T0619 1x106 cells / 1.0 ml Ask for price

Immortalized Mouse CD4+ CD8+ T Cells (MOHITO)

T0131 1x106 cells / 1.0 ml Ask for price

Human Bone Marrow CD34+ Stem Cells, Cryopreserved

BMCD34-C0.5M - Ask for price

Human Bone Marrow CD34+ Stem Cells, Cryopreserved

BMCD34-C1M - Ask for price

Human Bone Marrow CD34+ Stem Cells, Cryopreserved

BMCD34-C5M - Ask for price

Immortalized Human Oropharyngeal Cells

T0041 1x106 cells / 1.0 ml Ask for price

anti-Transferrin receptor on activated T-B- cells

518-A-01mg 0,1 mg
EUR 321
Description: anti-Transferrin receptor on activated T-B-, cells

anti-Transferrin receptor on activated T-B- cells

518-A-1000ug 1000 ug
EUR 1539
Description: anti-Transferrin receptor on activated T-B-, cells

The number of woven bones and the formation of the same cartilage (Huo Stage 6-7) was observed in the 3rd week after surgery in the human rights group (+) and at 6 weeks after human rights operations (-). The diameter of the callus was larger in the human rights group (+) and the difference was statistically significant (P <0.05) at 3 and 6 weeks after surgery. Although there were only statistically significant differences (P <0.05) in the 3rd week after surgery, the radiological score tended to be higher in the human rights group (+) in both weeks and 6th week after surgery. Cheap alternatives and easily accessible biological materials. Human rights can be used to support the treatment of fracture surgery, especially where bone healing is expected to last longer.

Leave A Comment